The EICNHL disease committee on pediatric primary mediastinal B cell lymphoma (PMBCL) addresses unmet clinical needs in a disease that predominantly affects adolescents and young adults. The group brings together expertise from pediatric oncology, pathology, biology, and statistics.
Since PMBCL is a rare disease, the disease committee aims to establish a joint European strategy for patients by performing biological and clinical studies together. Relevant recent publications of committee members have previously reported results from a prospective trial evaluating dose-adjusted EPOCH in PMBCL (Inter-B trial, Burke, JCO, 2021) and retrospective analyses from the BFM group (Knörr et al., Haematologica, 2021) and the French group (Dourthe et al., Haematologica, 2024). Currently, the group performs an analysis of clinical risk factors in pediatric patients treated with DA-EPOCH-R.
In-person meetings are part of EICNHL regular meetings. A first meeting of the PMBCL group for study development was held as a hybrid meeting in Utrecht on February 18 and 19, 2025.
Member of the committee:
Alexander, Sarah
Andres, Mara
Atterbaschi, Andishe
Auperin, Anne
Balague, Olga
Burke, Amos
Ceppi, Francesco
Chiang, Alan
Dourthe, Marie-Emilie
Jonas Sarah
Kabickova, Edita
Knörr, Fabian
Ljung Sass, Diana
Lyngsie Hjalgrim, Lisa
Mellgren, Karin
Meyer-Wentrup, Friederike (Convenor)
Minard, Veronique
Molina, Thierry
Smith, Owen
Turner, Susanne
Taj, Mary
Wößmann, Willi
Selection of recent PMBCL-related Publications of EICNHL members
Pillon, M., E. Carraro, L. Mussolin, V. Conter, A. Tondo, M. Arico, R. Mura, A. Sala, L. Vinti, S. Buffardi, P. Pierani, E. S. G. d’Amore and G. Basso (2018). “Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20.” Pediatr Blood Cancer 65(2).
Burke, G. A. A., V. Minard-Colin, A. Aupérin, S. Alexander, M. Pillon, R. Delgado, J. Zsíros, A. Uyttebroeck, P. Dartigues, R. R. Miles, B. Kazanowska, A. K. Chiang, S. Haouy, C. M. Bollard, M. Csoka, K. Wheatley, D. A. Barkauskas, P. C. Adamson, G. Vassal, C. Patte and T. G. Gross (2021). “Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: A multicenter phase II trial.” J. Clin. Oncol. 39(33): 3716-3724.
Knoerr, F., M. Zimmermann, A. Attarbaschi, E. Kabickova, B. Maecker-Kolhoff, S. Ruf, I. Kuhnle, M. Ebinger, A. K. Garthe, I. Simonitsch-Klupp, I. Oschlies, W. Klapper, B. Burkhardt and W. Woessmann (2021). “Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.” Haematologica 106(12): 3232-3235.
Dourthe, M. E., A. Auperin, C. Rigaud, M. Barbati, J. Bonneau, N. Buchbinder, M.-L. Couec, P. Dartigues, S. Ducassou, N. Garnier, S. Haouy, B. Jonca, A. Jourdain, A. Leruste, T. Molina, F. Montravers, M. Pasquet, A. Phulpin, M. Poirée, M. Simonin, A. Spiegel, A. Verschuur, T. Leblanc, J. Landman-Parker, C. Patte and V. Minard-Colin (2024). “Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with a FAB/ LMB-based chemotherapy regimen with rituximab.” Haematologica 109(11): 3790-3794.
Burke, G. A. A., L. Vinti, E. Kabickova, A. Beishuizen, N. Tacyildiz, A. Uyttebroeck, H. J. Kang, F. Luisi, V. Minard-Colin, B. Burkhardt, M. Tamegnon, S. Sun, M. Curtis, S. Deshpande, K. Nottage, A. Howes, S. Srinivasan, D. Bhojwani, R. Norris and M. Cairo (2023). “Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.” Blood Adv. 7(4): 602-610.